From genome to antivirals: SARS as a test tube

Yossef Kliger, Erez Y. Levanon, Doron Gerber

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

The severe acute respiratory syndrome (SARS) epidemic brought into the spotlight the need for rapid development of effective anti-viral drugs against newly emerging viruses. Researchers have leveraged the 20-year battle against AIDS into a variety of possible treatments for SARS. Most prominently, based solely on viral genome information, silencers of viral genes, viral-enzyme blockers and viral-entry inhibitors were suggested as potential therapeutic agents for SARS. In particular, inhibitors of viral entry, comprising therapeutic peptides, were based on the recently launched anti-HIV drug enfuvirtide. This could represent one of the most direct routes from genome sequencing to the discovery of antiviral drugs.

Original languageEnglish
Pages (from-to)345-352
Number of pages8
JournalDrug Discovery Today
Volume10
Issue number5
DOIs
StatePublished - 1 Mar 2005
Externally publishedYes

Fingerprint

Dive into the research topics of 'From genome to antivirals: SARS as a test tube'. Together they form a unique fingerprint.

Cite this